PATENT CLAIM ANALYSIS

Application Number: 15757687
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2019-02
Patent Classification: ["424", "204100"]

Abstract:
The present invention relates to augmenting the effects of adoptive T cell therapy, such as TVAX Immunotherapy, using adjunct treatment with an oncolytic virus, such as a vaccinia virus, to treat various types of cancer or other proliferative disorders. Immunomodulatory compounds can be used to further augment to effects of the therapy.

Claim (Index 31):
The method of  claim 30 , wherein each oncolytic virus is independently selected from the group consisting of vaccinia virus, reovirus, measles virus, mumps virus, adenovirus and herpes virus, vesicular stomatitis virus, newcastle disease virus, parvovirus, poliovirus, coxsackie virus, sindbis virus, seneca valley virus, maraba virus and combinations thereof.

Metadata:
- Claim Count in Document: 52.0
- Percentile: 90.0
- Lexical Diversity: 1.34884
- Patent Class: 424.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15892247', '14792424', '14004546', '15129916', '13470558']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7800653998391626
- 35 USC 102 Novelty (BERT): 0.5141539528672328
- Combined Prediction Score: 0.7534742551419695
- Mean Citation Score: 263.860032
- Max Citation Score: 281.17853
- Similarity Product: 175.0270658531934

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test